semaglutide heart issues cardiovascular outcomes align more closely with attained dose than achieved weight loss Semaglutide and Heart Disease: Safety

Published studies describe its interaction with GLP-1, GIP, and glucagon receptor systems in experimental models

doi: 10.1016/j.celrep.2024.114665 38 AktarTChenJEttelaieRHolmesM

Retatrutide Dosing: A Research Protocol Reference This guide compiles dosing information, reconstitution procedures, and storage guidelines for retatrutide based on published clinical trial literature and standard peptide handling protocols

Novo's recent FDA label expansion for Wegovy for reducing the risk of serious cardiovascular events provides a blueprint of how to expand the area these medicines can be helpful in

These effects were particularly strong among those at higher risk of aging-related diseases (42)